Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept for Retinal Angiomatous Proliferation
2021-001058-73Phase 4Terminated
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in exudative macular degeneration comparing Brolucizumab arm with Aflibercept arm (2 arms). Primary endpoint: Best corrected visual acuity (BCVA). Started Apr 2021; status: terminated.
02
Drugs
brolucizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2021-001058-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001058-73.